Categories

Category: Health Tech

Tom Knight, HealthcareDiversion.org

Tom Knight is the Chairman of HealthcareDiversion.org, a nonprofit that is trying to educate about the topic of drug theft from facilities. This happens both because medical professionals are addicts (and victims themselves) and also because of organized crime and resale. The consequences are awful, with patients receiving water instead of analgesic drugs, getting infections and often dying. And of course there’s a lot of liability and problems for those facilities when these issues are found out. What’s worse is that this problem is rampant. Tom has built a database to show just the tip of the iceberg of the problem. So come on a journey to a terrible health care problem you’ve never thought of that almost certainly affects you–Matthew Holt

Roon – the Demo and Interview

I was a little surprised that in the days of limitless content, AI, and all types of medical information being online a company could raise $15m to create a platform where actual doctors could answer specific questions that patients might have. Vikram Bhaskaran, the CEO is ex Pinterest and knows the consumer world well. Rohan Ramakrishna is  a neurosurgeon who is worried about the level of misinformation that he saw showing up in his clinic daily. So Roon is trying to build what might be the impossible, a free personalized (mostly video) guide for health powered by the world’s best experts. They gave me a tour of what they have built so far, and it’s both impressive, ambitious and has a way to go. It’s an interesting demo and it raises some interesting questions about how that knowledge will be shared in the very near future–Matthew Holt

Saving U.S. Manufacturing: Think Biotech, Not Cars

By KIM BELLARD

Amidst all the drama last week with tariffs, trade wars, and market upheavals, you may have missed that the National Security Commission on Emerging Biotechnology (NSCEB) issued its report: Charting the Future of Biotechnology. Indeed, you may have missed when the Commission was created by Congress in 2022; I know I did.

Biotechnology is a big deal and it is going to get much bigger. John Cumbers, founder and CEO of SynBiobeta, writes that the U.S. bioeconomy is now already worth $950Bn, and quotes McKinsey Global Institute as predicting that by 2040, biology could generate up to 60% of the world’s physical inputs, representing a $30 trillion global opportunity. Not an opportunity the U.S. can afford to miss out on – yet that is exactly what may be happening.

The NSCEB report sets the stakes:

We stand at the edge of a new industrial revolution, one that depends on our ability to engineer biology. Emerging biotechnology, coupled with artificial intelligence, will transform everything from the way we defend and build our nation to how we nourish and provide care for Americans.

Unfortunately, the report continues: “We now believe the United States is falling behind in key areas of emerging biotechnology as China surges ahead.”

Their core conclusion: “China is quickly ascending to biotechnology dominance, having made biotechnology a strategic priority for 20 years.1 To remain competitive, the United States must take swift action in the next three years. Otherwise, we risk falling behind, a setback from which we may never recover.”

NSCEB Chair Senator Todd Young elaborated:

The United States is locked in a competition with China that will define the coming century. Biotechnology is the next phase in that competition. It is no longer constrained to the realm of scientific achievement. It is now an imperative for national security, economic power, and global influence. Biotechnology can ensure our warfighters continue to be the strongest fighting force on tomorrow’s battlefields, and reshore supply chains while revitalizing our manufacturing sector, creating jobs here at home.

“We are about to see decades of breakthrough happen, seemingly, overnight…touching nearly every aspect of our lives—agriculture, industry, energy, defense, and national security,” Michelle Rozo, PhD, molecular biologist and vice chair of NSCEB, said while testifying before the April 8 House Armed Services Committee Subcommittee on Cyber, Information Technologies, and Innovation. Yet, she continued, “America’s biotechnology strengths are atrophying—dangerously.”

Continue reading…

We Need to Nationalize to Prevent Fraud

By MATTHEW HOLT

Two weeks ago I wrote an April Fool’s piece that claimed that Elon Musk and DOGE were going to nationalize American health care to save some money. That piece was half-joking but full-serious. 

If you look at what Musk is complaining about there are two major areas of “waste, fraud and abuse” in government spending. 

One is people directly employed by government agencies. Most of the people I’ve ever met in government work damn hard and for much less money than they’d get in the private sector. But you can of course find stories about useless government bureaucrats, who don’t do any work and pad their expense accounts. Those stories are probably about as true as Reagan’s pink Cadillac driving welfare queen in that there is some basis in reality for there being a tiny minority of bad actors, but the politics has far outrun the truth. (BTW that Welfare Queen article by Josh Levin in Slate is remarkable and very long!)

The other major area where Musk claims to be finding fraud is in work contracted out. There are of course lots of types of government work contracted out. If, like me, you’re old enough to remember the Iraq war, you probably are thinking of beltway bandits like Halliburton supplying any number of services to the military. (Remember when the Cheneys were baddies?). Another is the Blue Cross & Blue Shield plans who were the original contractors processing Medicare & Medicaid claims. Funnily enough they couldn’t actually deliver on that so in turn they outsourced it to Ross Perot at EDS and others like ACS, later Conduent. But there’s a ton more across every agency.

Musk & DOGE have been running around in the most ham-fisted way imaginable, axing both actual employees–including 20,000 of the 80,000 working at HHS– and allegedly slashing $150 billion in contracts. Of course on closer examination, many of the “contracts” were already over, or were made up. DOGE has been a pathetic piece of performance art that would be funny if it hadn’t ruined so many careers of people doing great work, or killed so many desperately poor children in poor countries.

The clever people at Brookings, (Elaine Kamarck and Paul Light) in a detailed piece on the topic, came up with an estimate of the ratio between direct employees and contractors.

Continue reading…

Elevare Law launches!

There’s a new health innovation law firm in town! Rebecca Gwilt & Kaitlyn O’Connor have started Elevare Law to help health tech companies. We spent a little time talking about the new firm and who it’s going to work with, and a lot about the different legal and regulatory challenges facing digital health companies. Deep dives into the regs around RPM, RTM & more, and also a lot about what we might expect from the FDA and the rest of the chaos in the new Administration. Plus a little about how AI helps lawyers be more efficient and a lot about how AI may or may not be influenced by health care regulation (TL:DL, it’s going to be slow & state by state) –-Matthew Holt

League Connect Digital Summit on May 7

I’m thrilled to be working with League and I’ll be MC-ing health care’s must-attend virtual CX event, League Connect Digital Summit on May 7. 

An immersive day of inspiration, insights, and incredible speakers is headlined by Moneyball & Big Short Best-Selling Author, Michael Lewis and @HighmarkHealth CEO, @DavidHolmberg, as well as many more.

More than just theory, at the Summit you’ll get actionable strategies and everything you need to drive health care CX forward. – Matthew Holt

Register today to save your spot

Bevey Miner, Consensus Cloud Solutions

Consensus is taking fax data, received by rural clinics, post acute, substance abuse clinics, home health et al, and helping them put it into their systems of records–which are in general not FHIR-enabled. They allow those facilities & services to receive referrals from acute care hospitals. By 2027 many of these standards are going to need to be FHIR enabled. Bevey Miner, EVP at Consensus, is a health care veteran who is working on both a policy and technology level to improve access to care, and thinks a lot about what unstructured data means in a world where we are trying to use data for AI and more. Super interesting chat about the murky backwaters of health care data and services. As Bevey says, “Not everyone is going to be Epic to Epic to Epic”–Matthew Holt

Platform Shift: From EHRs to UDHPs (Unified Digital Health Platforms) – – Section 2

By VINCE KURAITIS, GIRISH MURALIDHARAN & JODY RANCK

This entry is Section 2 of part 3 of 3 in the series Platforming Healthcare — The Long View. This essay is the next in the series entitled “Platforming Healthcare — the Long View”. The series presents a 30-Year Framework for Platforming Healthcare. An updated v2.0 of a graphic depicting this 30-Year Framework is shown above.

Today’s post is section 2 and will continue to describe and discuss a potential successor to the EHR era — Unified Digital Health Platforms (UDHPs). Here’s an overview:

  • Mayo Clinic Platform
  • Business and Strategic Implications of UDHPs
  • APPENDIX: Additional Readings on UDHPs

Mayo Clinic Platform: Healthcare platforms and AI

The Mayo Clinic Platform (MCP)was launched several years ago with the goal of building the future Mayo Clinic business model that could move beyond the bricks-and-mortar approach to traditional healthcare and open up new avenues for products and services. The adoption of a platform business model was considered essential to serving patients beyond the traditional Mayo Clinic geography as well as a way to incentivize innovation in AI and decentralized care in the home. 

A large longitudinal database with both structured and unstructured data provides a foundation for the MCP, particularly in respect to catalyzing innovation in clinical applications of AI. The database called Mayo Clinic Platform Discover has over 7.3 million de-identified patient records that can be used for training AI models as well as in research and discovery for early-stage startups in particular who wish to join the MCP ecosystem. The dataset is referred to as “Data behind glass” for the privacy and security standards that are needed to create the bedrock for a collaborative ecosystem.

Source: Mayo Clinic Platform Playbook

MCP is a three-sided market that has solution developers, data providers, and clinicians composing the three sides. MCP acts as the orchestrator of the ecosystem and additional partners such as Mercy have joined as data contributors in the MCP component called Mayo Clinic Platform Connect. These are the primary components of the platform. 

The Mayo Clinic Platform Playbook identifies six key success factors:

  • A privacy-protecting, secure collaborative environment with de-identified data from global sources. Longitudinal databases of patient records are vital to clinical research and the development of new clinical decision-support tools, therapeutics, and digital health solutions. Privacy and security need to be maintained to protect the trust of Mayo Clinic’s patients.
  • Breadth and depth of patient data must be sufficient to generate insights for both rare and common diseases.
  • Seamless capabilities to both ingest diverse data sources (e.g. -omic (genome, metabolome, etc.), EHR, wearables, social determinants of health (SDoH)) and to deliver actionable insights at the point of care.
  • Cutting-edge data science analytic tools, robust computing power, and uniform data standards.
  • Strong governance to assume security, scientific validity, interoperability and validation of technologies fit for purpose.
  • Pathways for commercialization of effective, validated solutions.

MCP vets startups and more mature technology vendors through a process that can begin with providing access to the longitudinal database for developing and training models (early-stage startups) to scaling solutions across MCP and affiliated hospitals with Mayo Clinic. The robust governance structure and integration with MCP makes scaling into other systems much more feasible.

AI governance is a core component of the MCP and why they were one of the original sponsors of the Coalition for Health AI (CHAI) to bring together leading industry players to create the standards for responsible AI across validation, explainability, and transparency.  Ensuring that AI tools have been rigorously validated is necessary for clinician adoption of AI as well as maintaining the trust of patients. These standards act as a kind of “rules of the road” for technology solution providers on the MCP.

Continue reading…

Platform Shift: From EHRs to UDHPs (Unified Digital Health Platforms)- Section 1

By VINCE KURAITIS, GIRISH MURALIDHARAN & JODY RANCK

This entry is part 3 of 3 in the series Platforming Healthcare — The Long View. This essay is the next in the series entitled “Platforming Healthcare — the Long View”. The series presents a 30-Year Framework for Platforming Healthcare. An updated v2.0 of a graphic depicting this 30-Year Framework is shown below.

30 Year

This entry is part 3 of 3 in the series Platforming Healthcare — The Long View. This essay is the next in the series entitled “Platforming Healthcare — the Long View”. The series presents a 30-Year Framework for Platforming Healthcare. An updated v2.0 of a graphic depicting this 30-Year Framework is shown above.

Today’s post will describe and discuss a potential successor to the EHR era — Unified Digital Health Platforms (UDHPs). Here’s an overview:

  • Background and Environmental Trends
  • Gartner’s Key Role in Characterizing the UDHP Movement
  • UDHP Value Propositions
  • Examples of UDHPs
    • ServiceNow

Later this week THCB will run the second section which will include analysis of the Mayo Clinic Platform.

      Background and Environmental Trends

      Healthcare is fragmented. Data is not standardized and has existed in silos. Patients and clinicians have disjointed experiences. Payment structures create conflicting incentives.

      Electronic Health Records (EHRs) were once touted as the key solution for transforming healthcare to a modern, digitally-enabled industry. Yet, they continue to frustrate clinicians with poor UI/UX and largely fulfill a primary role as a system of record to document claims submissions. 

      Recent technological and business trends have begun transforming healthcare into a more unified and integrated experience: 

      • HITECH (in the U.S.) drove the adoption of electronic health records across the industry 
      • Standards-compliant data models and APIs across various solutions are allowing third-party integrations to add new functionality 
      • Value-based care (VBC) and value-based payment (VBP) models incentivize improving quality rather than maximizing fee-for-service volumes 
      • AI’s emergence and adoption in healthcare fuels the need for more – and better – data and data liquidity. 
      • New competitors in healthcare (Big Tech, Big Retail, digital health ventures) compete based on improving patient experience, advancing VBC and VBP models, and integrated data and analytics 
      • Accessible cloud computing infrastructure is enabling a plethora of **-as-a-Service business models 

      Healthcare organizations want integrated solutions, not more point solutions. See the previous blog post in this series — “Beyond Awareness: Understanding the Magnitude of Point Solution Fatigue in Healthcare”.

      Gartner’s Key Role in Characterizing the UDHP Movement

      The trends and forces listed above open the door and create the need for a new category of enterprise software – Unified Digital Health Platforms (UDHPs). 

      A December 2022 Gartner Market Guide report characterized the long-term potential:

      The DHP shift will emerge as the most cost-effective and technically efficient way to scale new digital capabilities within and across health ecosystems and will, over time, replace the dominant era of the monolithic electronic health record (EHR).

      While Gartner uses the term “Digital Health Platform (DHP), we use the term “Unified Digital Health Platform” because 1) it’s more descriptive of the architecture and its capabilities, and 2) it distinguishes UDHPs from the thousands of other digital health platforms that vary highly in function.

      The DHP Reference Architecture is illustrated in a blog post by Better. Note that UDHPs are depicted as “sitting on top” of EHRs and other siloed sources of health data:

      Gartner continues to update its market reports on UDHPs. An April 2024 update is entitled: “Innovation Insight: Digital Health Platforms Accelerate Transformation”. As of the date of publishing this blog post, Altera is offering a complimentary copy of Gartner’s 2024 report on UDHPs.  

      This blog post is intended to focus more on the business and strategy implications of UDHPs. We strongly recommend reading Gartner’s April 2024 report on UDHPs to gain a more technical perspective.

      Continue reading…

      Emory, Balloon Angioplasty, and the Musk Attack on Medical Diplomacy

      By MIKE MAGEE

       “The recently announced limitation from the NIH on grants is an example that will significantly reduce essential funding for research at Emory.”       

                                                    Gregory L. Fenes, President, Emory University 

      In 1900, the U.S. life expectancy was 47 years. Between maternal deaths in child birth and infectious disease, it is no wonder that cardiovascular disease (barely understood at the time) was an afterthought. But by 1930, as life expectancy approached 60 years, Americans stood up and took notice. They were dropping dead on softball fields of heart attacks. 

      Remarkably, despite scientific advances, nearly 1 million Americans ( 931,578) died of heart disease in 2024. That is 28% of the 3,279,857 deaths last year. 

      The main cause of a heart attack, as every high school student knows today, is blockage of one or more of the three main coronary arteries – each 5 to 10 centimeters long and four millimeters wide. But at the turn of the century, experts didn’t have a clue. When James Herrick first suggested blockage of the coronaries as a cause of heart seizures in 1912, the suggestion was met with disbelief. Seven years later, in 1919, the clinical findings for “myocardial infarction” were associated with ECG abnormalities for the first time. 

      Scientists for some time had been aware of the anatomy of the human heart, but it wasn’t until 1929 that they actually were able to see it in action. That was when a 24-year old German medical intern in training named Werner Forssmann came up with the idea of threading a ureteral catheter through a vein in the arm into his heart. 

      His superiors refused permission for the experiment. But with junior accomplices, including an enamored nurse, and a radiologist in training, he secretly catheterized his own heart and injected dye revealing for the first time a live 4-chamber heart. Two decades would pass before Werner Forssmann’s “reckless action” was rewarded with the 1956 Nobel Prize in Medicine. But another two years would pass before the dynamic Mason Sones, Cleveland Clinic’s director of cardiovascular disease, successfully (if inadvertently) imaged the coronary arteries themselves without inducing a heart attack in his 26-year old patient with rheumatic heart disease. 

      But it was the American head of all Allied Forces in World War II, turned President of the United States, Dwight D.Eisenhower, who arguably had the greatest impact on the world focus on this “public enemy #1.” His seven heart attacks, in full public view, have been credited with increasing public awareness of the condition which finally claimed his life in1969. 

      Cardiac catheterization soon became a relatively standard affair. Not surprisingly, less than a decade later, on September 16, 1977, an East German physician, Andreas Gruntzig performed the first ballon angioplasty, but not without a bit of drama. 

      Dr. Gruntzig had moved to Zurich, Switzerland in pursuit of this new, non-invasive technique for opening blocked arteries. But first, he had to manufacture his own catheters. He tested them out on dogs in 1976, and excitedly shared his positive results in November that year at the 49th Scientific Session of the American Heart Association in Miami Beach. 

      He returned to Zurich that year expecting swift approval to perform the procedure on a human candidate. But a year later, the Switzerland Board had still not given him a green light to use his newly improved double lumen catheter. Instead he had been invited by Dr. Richard Myler at the San Francisco Heart Institute to perform the first ever balloon coronary artery angioplasty on an awake patient.

      Gruntzig arrived in May, 1977, with equipment in hand. He was able to successfully dilate the arteries of several anesthetized patients who were undergoing open heart coronary bypass surgery. But sadly, after two weeks on hold there, no appropriate candidates had emerged for a minimally invasive balloon angioplasty in a non-anesthetized heart attack patient. 

      In the meantime, a 38-year-old insurance salesman, Adolf Bachmann, with severe coronary artery stenosis, angina, and ECG changes had surfaced in Zurich. With verbal assurances that he might proceed, Gruntzig returned again to Zurich. The landmark procedure at Zurich University Hospital went off without a hitch, and the rest is history. 

      Continue reading…